Lemaitre Vascular

Q2 FY2026 EarningsQ2 FY2026 revenue of $70.4M slightly missed the consensus of $71.5M, while Diluted EPS of $0.74 fell below the expected $0.81. Gross margin came in at 72.1%, in-line with expectations, despite sales price increases being offset by manufacturing inefficiencies. The variance in earnings was primarily driven by higher R&D expenses (+37% YoY) related to allograft facility transfers and a higher-than-expected diluted share count from the assumed conversion of Senior Convertible Notes.